The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19

Details

Project Status:

Active

Project Line:

Health Technology Review

Project Sub Line:

Technology Review

Project Number:

HE0051-000

This report aims to estimate the impacts of providing tocilizumab as a treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.

Last Updated : October 8, 2024